Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Tema Cardiovascular and Metabolic ETF (HRTS)

Tema Cardiovascular and Metabolic ETF (HRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing Stocktwits - Thu Feb 13, 2025

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

TCAF : 37.39 (+0.86%)
ASND : 239.92 (-0.30%)
IBB : 171.29 (+2.23%)
HRTS : 34.75 (+1.25%)
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes Stocktwits - Wed Jan 15, 2025

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

VXF : 211.20 (+0.98%)
KROS : 11.35 (+0.44%)
HRTS : 34.75 (+1.25%)
XBI : 127.12 (+2.52%)
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR Zacks Investment Research - Thu Oct 17, 2024

For Immediate ReleaseChicago, IL – October 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 39.78 (+3.11%)
LLY : 1,008.39 (+1.82%)
HRTS : 34.75 (+1.25%)
PPH : 107.14 (+1.13%)
THNR : 25.11 (+1.83%)
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win Zacks Investment Research - Wed Oct 16, 2024

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...

NVO : 39.78 (+3.11%)
LLY : 1,008.39 (+1.82%)
HRTS : 34.75 (+1.25%)
PPH : 107.14 (+1.13%)
THNR : 25.11 (+1.83%)
Tap the Weight-Loss Drug Market With These ETFs
Tap the Weight-Loss Drug Market With These ETFs Zacks Investment Research - Wed Sep 18, 2024

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

NVO : 39.78 (+3.11%)
OZEM : 32.31 (+1.20%)
LLY : 1,008.39 (+1.82%)
HRTS : 34.75 (+1.25%)
RHHBY : 54.6500 (-1.34%)
THNR : 25.11 (+1.83%)
Not Sure Which Weight Loss Stock to Buy? Invest in This ETF Baystreet - Mon Jul 15, 2024

Many healthcare companies have been eagerly developing new weight loss drugs in an effort to cash in ...

VKTX : 33.61 (+1.91%)
LLY : 1,008.39 (+1.82%)
HRTS : 34.75 (+1.25%)
Don’t Know Which Weight-Loss Stock Will Be the Biggest Winner? Invest in This ETF Instead Baystreet - Tue Nov 28, 2023

There’s a lot of excitement in the weight-loss industry these days. Between Ozempic, Wegovy, Mounjaro, ...

NVO : 39.78 (+3.11%)
HRTS : 34.75 (+1.25%)
LLY : 1,008.39 (+1.82%)

Barchart Exclusives

2 High-Yield Dividend Stocks to Buy Now Amid the U.S.-Iran War Barchart - Mon Mar 9, 6:30PM CDT
J.P. Morgan’s more bullish stance on select European majors makes sense here, because Eni and TotalEnergies combine mid‑single‑digit yields, below‑sector valuation multiples, and diversified upstream, downstream, and renewables portfolios that can monetize a sustained Middle East risk premium while still paying investors to wait. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot